

Erratum to: “A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma”

Kjersti Lia,¹⁻³ Rasmus Rask Kragh Jørgensen,⁴⁻⁶ Per Wikman,⁷ Bente L. Wold,³ Ninja Övergaard,^{7,8} Øystein Fluge,⁹ Unn-Merete Fagerli,^{10,11} Hanne Bersvendsen,¹² Idun B. Bø,^{13,14} Sameer Bhargava,^{15,16} Daniel Molin⁷ and Alexander Fosså^{3,17}

¹Medical Department, Bærum Hospital, Vestre Viken Hospital Trust, Gjøttum, Norway; ²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ³Department of Oncology, Oslo University Hospital, Oslo, Norway; ⁴Center for Clinical Data Science, Aalborg University and Aalborg University Hospital, Aalborg, Denmark; ⁵Department of Hematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark; ⁶Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; ⁷Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden; ⁸Department of Clinical Pathology, Uppsala University, Uppsala, Sweden; ⁹Department of Oncology, Haukeland University Hospital, Bergen, Norway; ¹⁰Department of Oncology, St. Olavs Hospital, Trondheim, Norway; ¹¹Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; ¹²Department of Oncology, University Hospital of North Norway, Tromsø, Norway; ¹³Department of Hematology, Stavanger University Hospital, Stavanger, Norway; ¹⁴Institute of Clinical Medicine 2, University of Bergen, Bergen, Norway; ¹⁵Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; ¹⁶South-Eastern Norway Regional Health Authority, Oslo, Norway and ¹⁷KG Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo, Norway


Correspondence: K. Lia
kjerli@vestreviken.no

Received: February 25, 2026.
Accepted: February 25, 2026.


<https://doi.org/10.3324/haematol.2026.289423>

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license

In our original publication,¹ the overall survival data that were reported contained minor inaccuracies in the external validation cohort. The corrected overall survival data are provided herein. For fit patients, median overall survival (OS) was not reached and 5-year OS was 79% (95% CI: 73-84%). Five-year OS was 38% (95% CI: 33-42%) for unfit patients and 4% (95% CI: 0-24%) for frail patients. The correct Figure 3, presented here, includes the number at risk at five years. The new *Online Supplementary Figure S7* (see below) includes the number at risk at five years.




Continued on following page.




Correct Figure 3. Progression-free and overall survival up until five years according to frailty groups in the external validation cohort. (A) All patients. (B) Patients with limited disease. (C) Patients with advanced disease.

Correct Online Supplementary Figure S7.



Continued on following page.



Progression-free and overall survival up until five years according to frailty groups in the patients from the validation cohort with complete treatment data. (A) All patients. (B) Patients with limited disease. (C) Patients with advanced disease.

References

1. Lia K, Jørgensen RRK, Wikman P, et al. A simplified frailty score predicts outcome in curatively treated older patients with

classical Hodgkin lymphoma. Haematologica. 2025;110(10):2356-2366.